NDC 59368-385 - Micardis HCT
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 59368-385
- Package NDCs from labels
- 59368-385-01
- Manufacturer
- Praxis, LLC
- Effective date
- 2023-01-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Micardis HCT - Praxis, LLC | Praxis, LLC | 2023-01-01 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Northwind Health Company, LLC | db895e64-3f97-9201-e053-2a95a90ac7ef | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | Solco Healthcare US, LLC | bdca31d3-60b1-4659-aef7-56530b4f9039 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Telmisartan | TELMISARTAN | A-S Medication Solutions | eaed12cd-5bfe-4c98-9afc-025ed86a294f | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | U5SYW473RQ |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | A-S Medication Solutions | bc8b9ae2-8263-4624-8629-4f856392f9da | 2025-12-30 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Teva Pharmaceuticals USA, Inc. | deafd195-7a1b-4ad8-a371-2cd9f433dea5 | 2025-12-29 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE | Northwind Health Company, LLC | 076017ce-8aad-1336-e063-6394a90a76b5 | 2025-12-26 | Warnings, Adverse reactions | 0J48LPH2TH |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Northwind Health Company, LLC | 08f3885e-dfde-79e4-e063-6394a90a4c09 | 2025-12-26 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Alembic Pharmaceuticals Inc. | acecced9-2a61-435d-b7d4-b151cb7b7e5d | 2025-12-26 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| ATACAND HCT | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | ANI Pharmaceuticals, Inc. | d91152c4-66ba-466f-b4f9-0da628d42b1d | 2025-12-22 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Candesartan Cilexetil and Hydrochlorothiazide | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | ANI Pharmaceuticals, Inc. | bd8d318d-167a-4b26-935d-265dde3193de | 2025-12-22 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Lisinopril and Hydrochlorothiazide | LISINOPRIL AND HYDROCHLOROTHIAZIDE | QPharma, Inc. | c80b2164-3795-6668-e053-2a95a90a4d45 | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Irbesartan and Hydrochlorothiazide | IRBESARTAN AND HYDROCHLOROTHIAZIDE | Aurobindo Pharma Limited | 466dd0d2-9815-4c3e-b66b-d0732b3ba8e9 | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Irbesartan and Hydrochlorothiazide | IRBESARTAN AND HYDROCHLOROTHIAZIDE | Unichem Pharmaceuticals (USA), Inc. | 181324c5-256f-4570-a0bb-8bc908deb2e2 | 2025-12-18 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE | A-S Medication Solutions | f9faec8a-2b71-47bb-a296-48ecbce9af50 | 2025-12-16 | Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | QPharma, Inc. | c9c44c37-bb49-4364-9293-3c8fd51b759e | 2025-12-16 | Warnings, Adverse reactions | 0J48LPH2TH |
| INZIRQO | HYDROCHLOROTHIAZIDE | ANI Pharmaceuticals, Inc. | 41aaea48-6c1b-42c8-a96f-5923d49dc934 | 2025-12-16 | Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | QPharma, Inc. | 9cd5d16e-3db7-4b25-847d-6de91543463b | 2025-12-15 | Warnings, Adverse reactions | 0J48LPH2TH |
| Exforge HCT | AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE | Novartis Pharmaceuticals Corporation | 18d7820d-471f-4ee2-9ec6-25d8d27c77de | 2025-12-12 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Chartwell RX, LLC | 4e43dd27-3f4b-4205-a26e-6ecaa8281347 | 2025-12-10 | Warnings, Adverse reactions | 0J48LPH2TH |
| TELMISARTAN | TELMISARTAN | Chartwell RX, LLC. | beaaf383-730f-4411-b5e7-15c32b53a338 | 2025-12-10 | Boxed warning, Warnings, Adverse reactions | U5SYW473RQ |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.